证券代码：301367 证券简称：怡和嘉业 公告编号：2025-031 | | 变更前 | 变更后 | | --- | --- | --- | | 中文名称 | 北京怡和嘉业医疗科技股份有限公司 | 北京瑞迈特医疗科技股份有限公司 | | 英文名称 | BMC Medical Co., Ltd. | BMC Medical Co., Ltd. | | 证券简称 | 怡和嘉业 | 瑞迈特 | | 证券代码 | 301367 | 301367 | 北京怡和嘉业医疗科技股份有限公司 关于拟变更公司名称、证券简称及修订《公司章程》 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召 开的第三届董事会第十三次会议审议通过了《关于拟变更公司名称、证券简称及修订< 公司章程>的议案》，为使公司名称能更准确地反映公司的发展方向和业务特征，更好 地提升企业品牌形象和品牌价值，公司拟对公司名称、证券简称进行变更，该事项尚需 提交公司 2024 年年度股东大会审议。现将相关情况公告如下： ...

Core Viewpoint - The Chinese medical device industry is focusing on technological breakthroughs and practical applications to navigate the complex global political and economic landscape, as discussed at the 91st China International Medical Equipment Fair (CMEF) [2] Group 1: Industry Trends and Innovations - Companies are leveraging AI technology to enhance product competitiveness and are seizing opportunities from domestic consumption promotion initiatives [3] - The exhibition showcased a wide range of digital products and AI innovations, indicating a shift towards intelligent technology and ecosystem collaboration [3] - The introduction of national policies like "national subsidies" and "trade-in for new consumption" has significantly boosted domestic sales of medical devices [4][8] Group 2: Company Performance and Market Position - The brand "瑞迈特" under the company has achieved a global market share of 12.4% in 2023, ranking second globally, and holds a 30.6% share in the domestic market, leading the sector [6] - The company's overseas revenue reached 219 million yuan, accounting for 57.20% of total revenue, while domestic revenue was 164 million yuan, making up 42.80% [6] - The company perceives the domestic market as having stronger certainty compared to overseas markets, but it remains committed to global expansion [6][7] Group 3: Consumer Behavior and Policy Impact - The introduction of subsidies has led to increased sales, with significant price reductions for products like the 瑞迈特 E5 B20A Plus respiratory machine due to government and platform subsidies [8] - The recent government initiative to support consumption with a special bond of 300 billion yuan aims to stimulate short-term consumption and encourage technological upgrades in products [8] Group 4: Future Development and Strategic Focus - The company is focusing on enhancing its product offerings through AI and digital technologies, aiming to provide comprehensive health management rather than just treating illnesses [9][10] - The company plans to strengthen its clinical channel to build brand image and engage with healthcare professionals, while also investing in algorithm updates and new material research [10]

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-013 北京怡和嘉业医疗科技股份有限公司 关于回购公司股份期限届满暨回购完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开公司第三届董事会第七次会议和第三届监事会第七次会议，审议通过 《关于回购公司股份方案的议案》，同意公司以不低于人民币 3,000 万元（含本 数）且不超过人民币 6,000 万元（含本数）的超募资金以集中竞价交易方式回购 公司已发行的人民币普通股（A 股）股票，用于实施员工持股计划或股权激励， 回购价格不超过人民币 144.02 元/股（含本数）。回购股份的实施期限为自公司 董事会审议通过回购方案之日起不超过 12 个月。 具体内容详见公司于 2024 年 4 月 12 日、2024 年 4 月 13 日、2024 年 4 月 20 日刊登在巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的 公告》（公告编号：2024-020）、《关于回购股份事项前十大 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-012 北京怡和嘉业医疗科技股份有限公司 监事会关于 2025 年限制性股票激励计划 激励对象名单的公示情况说明及核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 28 日 召开第三届董事会第十二次会议和第三届监事会第十二次会议，审议通过了《关于<北 京怡和嘉业医疗科技股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议 案》等相关议案。2025 年限制性股票激励计划（以下简称"本激励计划"）具体内容详 见公司于 2025 年 3 月 29 日披露在巨潮资讯网（http://www.cninfo.com.cn）上的相关公 告。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）《深 圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）《深圳证券交易所创业 板上市公司自律监管指南第 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-011 北京怡和嘉业医疗科技股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内披露截 至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购公司股份的进展情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开公司第三届董事会第七次会议和第三届监事会第七次会议，审议通过 《关于回购公司股份方案的议案》。回购股份的实施期限为自公司董事会审议通 过回购方案之日起不超过 12 个月。 具体内容详见公司于 2024 年 4 月 12 日、2024 年 4 月 13 日、2024 年 4 月 20 日刊登在巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的 公告》（2024-020）、《关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告》 ...

Group 1 - The company announced a restrictive stock incentive plan aimed at promoting the implementation of its long-term strategy, granting 704,000 shares to 54 executives and key personnel, representing approximately 0.79% of the total share capital, with an exercise price of 38.66 yuan per share and performance assessment targets based on revenue for 2025 and 2026 [1][2] - For 2024, the company expects a significant decline in net profit, projected to drop by 44.5% to 55.6% year-on-year, primarily due to a decrease in revenue influenced by inventory destocking in the U.S. market, although there has been a quarter-on-quarter improvement in Q3 2024 [1][2] - The performance assessment targets for the restrictive stock plan are set at no less than 1.01 billion yuan for 2025 and 1.21 billion yuan for 2026, indicating a growth expectation of 19.8% [2] Group 2 - The stock incentive plan is seen as a positive signal for the company's long-term strategy, despite the downward adjustment of revenue forecasts for 2024, 2025, and 2026 to 801 million, 962 million, and 1.129 billion yuan respectively [3] - The company has reached a cooperation agreement with RH Company, expanding its distribution area to include Canada and increasing the range of products related to lung disease, which is expected to enhance market share in the U.S. [2][3]

Investment Rating - The investment rating for the company is "Buy" [4][18]. Core Views - The company has released a stock incentive plan for 2025, aiming to solidify growth certainty with a target of 20% year-on-year growth for 2026 [3]. - The U.S. ventilator market is gradually stabilizing, with a projected recovery in 2025, leading to potential high growth for the company [4]. - The domestic business share is steadily increasing, and there is potential for market share growth overseas, particularly in the U.S. and Europe [4]. Summary by Sections Stock Incentive Plan - The stock incentive plan involves granting a total of 704,000 restricted shares, accounting for 0.79% of the company's total share capital of 89.6 million shares, to 54 individuals including senior management and key technical personnel [3]. Financial Performance and Forecast - The company expects revenue for 2024 to decline by 21% to 884 million yuan, with a net profit forecast of 161 million yuan, a decrease of 46% [4]. - Revenue growth is projected to rebound to 30% in 2025 and 28% in 2026, with net profit growth of 28% and 31% respectively [4][5]. - The earnings per share (EPS) is expected to be 1.80 yuan in 2024, increasing to 2.31 yuan in 2025 and 3.03 yuan in 2026 [5]. Market Position and Strategy - The company is positioned as a leading domestic manufacturer of ventilators, with a strong market share in the U.S. and plans for global expansion [4]. - The international business accounted for 60.55% of revenue in the first three quarters of 2024, indicating a growing reliance on overseas markets [4].

Group 1 - The company held its 12th meeting of the third Supervisory Board on March 28, 2025, with all three supervisors present, including one via telecommunication [2][4] - The meeting approved the draft of the 2025 Restricted Stock Incentive Plan, which aligns with relevant laws and regulations, aiming to motivate management and core personnel for sustainable development [3][5] - The plan will be submitted for shareholder meeting approval [5][7] Group 2 - The company also held its 12th meeting of the third Board of Directors on March 28, 2025, with all nine directors present [11][13] - The Board approved the draft of the 2025 Restricted Stock Incentive Plan and its summary, designed to attract and retain talent while aligning interests among shareholders, the company, and core teams [12][14] - The Board proposed to authorize the Board of Directors to handle matters related to the implementation of the incentive plan, which includes various responsibilities and adjustments as necessary [15][17] Group 3 - The company plans to hold its first temporary shareholder meeting of 2025 on April 17, 2025, using a combination of on-site and online voting [20][21] - The meeting will address the approval of the incentive plan and other related matters [19][20]

北京怡和嘉业医疗科技股份有限公司 2025 年限制性股票激励计划激励对象名单 一、本激励计划激励对象获授的限制性股票分配情况 本激励计划授予的限制性股票在各激励对象间的分配情况如下表所示： | 姓名 | 职务 | 获授的限制性股 | 占授予总 | 占目前总股 | | --- | --- | --- | --- | --- | | | | 票的份额（万股） | 量的比例 | 本的比例 | | 暴楠 | 副总经理、财务总监 | 2.20 | 3.13% | 0.02% | | 郑芳 | 副总经理 | 2.20 | 3.13% | 0.02% | | 核心技术（业务）人员（52 | 人） | 66.00 | 93.75% | 0.74% | | | 合计 | 70.40 | 100.00% | 0.79% | 注：1、上述任何一名激励对象通过全部有效的股权激励计划获授的本公司股票均未超过公司总股本的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会时公司股本总 额的 20%。 2、本激励计划激励对象不包括公司独立董事、监事，也不包括单独或合计持有公司 5%以上股份的股 东或实际控制 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-010 北京怡和嘉业医疗科技股份有限公司 关于独立董事公开征集表决权的公告 根据中国证券监督管理委员会（以下简称"中国证监会"）、《上市公司股 权激励管理办法》（以下简称"《管理办法》"）的有关规定，并经北京怡和嘉 业医疗科技股份有限公司（以下简称"公司"）其他独立董事的同意，独立董事 孙培睿作为征集人，就公司拟定于2025年4月17日召开的2025年第一次临时股东 大会审议的2025年限制性股票激励计划相关议案向公司全体股东公开征集表决 权。 独立董事孙培睿保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、征集人的基本情况 本公司及董事会全体成员保证告内容与信息披露义务人提供的信息一致。 特别声明： 1. 本次征集表决权为依法公开征集，征集人孙培睿符合《中华人民共和国 证券法》第九十条、《上市公司股东大会规则》第三十一条、《公开征集上市公 司股东权利管理暂行规定》第三条规定的征集条件； 2. 截至本公告披露日，征集人未持有公司股份。 征集人仅就股东大会部分提案征集表决权，如被征集人或其代理人在委托征 集人对 ...